Fyhrquist F, Karppinen K, Honkanen T, Saijonmaa O, Rosenlöf K
Minerva Institute for Medical Research, Helsinki, Finland.
J Intern Med. 1989 Oct;226(4):257-60. doi: 10.1111/j.1365-2796.1989.tb01390.x.
Eighteen patients with dilated cardiomyopathy (three female, mean age 57 years), were treated for 48 weeks with enalapril added to digoxin and diuretic therapy for congestive heart failure of New York Heart Association (NYHA) functional class II (three patients). III (eight patients) and IV (seven patients), respectively. Serum levels of erythropoietin (EPO) were raised at the start (37 +/- 12.8 pmol 1(-1); mean +/- SD) and were normalized during enalapril treatment (17.5 +/- 9.9 pmol 1(-1) at 48 weeks; P less than 0.001). Serum EPO correlated at the start with NYHA functional class (r = 0.68; P less than 0.05). Normalization of elevated serum EPO concentrations during treatment with enalapril paralleled clinical and haemodynamic improvement, and probably reflected relief from renal hypoxia.
18例扩张型心肌病患者（3例女性，平均年龄57岁），针对纽约心脏协会（NYHA）心功能II级（3例患者）、III级（8例患者）和IV级（7例患者）的充血性心力衰竭，在接受地高辛和利尿剂治疗的基础上加用依那普利治疗48周。促红细胞生成素（EPO）血清水平在开始时升高（37±12.8 pmol 1(-1)；均值±标准差），在依那普利治疗期间恢复正常（48周时为17.5±9.9 pmol 1(-1)；P<0.001）。血清EPO在开始时与NYHA心功能分级相关（r = 0.68；P<0.05）。依那普利治疗期间血清EPO浓度升高的情况恢复正常与临床和血流动力学改善平行，可能反映了肾缺氧缓解。
